Αρχική World News A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable...

A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable Tolerability in Advanced RCC

In the COSMIC-021 study, cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings are published by Dr. Sumanta K. Pal of the Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center in Duarte, CA, USA and colleagues on 7 September 2021 in the Journal of Clinical Oncology (JCO).

COSMIC-021 is evaluating the combination of cabozantinib plus atezolizumab in patients with various advanced solid tumours, including clear cell and non–clear cell RCC. Cabozantinib plus atezolizumab showed encouraging antitumour activity in patients with clear cell RCC in the dose-escalation stage of COSMIC-021 and in expansion cohorts of other solid tumours. In the latest article published in the JCO, the study team reports the results for all patients with advanced clear cell RCC and non-clear cell RCC enrolled in the study.

This phase Ib study enrolled adult patients with advanced RCC. A dose-escalation stage was followed by expansion cohorts. For cohort expansion, prior systemic therapy was not permitted for clear cell RCC, but it was allowed for non-clear cell RCC. Patients received oral cabozantinib 40 mg once a day (clear cell RCC and non-clear cell RCC) or 60 mg once a day (clear cell RCC only) plus 1,200 mg of atezolizumab intravenously, once every 3 weeks. The study primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. The secondary endpoint was safety.

In total, 102 patients were enrolled. Median follow-up was 25.8, 15.3, and 13.3 months for the 40 mg clear cell RCC, 60 mg clear cell RCC and non-clear cell RCC groups, respectively.

The ORR was 53% (80% confidence interval [CI] 41 to 65) in the 40 mg clear cell RCC group and 58% (80% CI 46 to 70) in the 60 mg clear cell RCC group, with complete response of 3% and 11%, respectively. Median progression-free survival (mPFS) which was exploratory endpoint was 19.5 and 15.1 months. In non-clear cell RCC group, ORR was 31% (80% CI 20 to 44), all partial responses; mPFS was 9.5 months.

Grade 3 or 4 treatment-related adverse events (TRAEs) were reported by 71% of patients in the 40 mg clear cell RCC group, 67% in the 60 mg clear cell RCC group, and 38% in the non-clear cell RCC group. TRAEs leading to discontinuation of both agents occurred in 15%, 6%, and 3% of patients, respectively. There were no grade 5 TRAEs.

The authors concluded that they observed encouraging antitumour activity with the combination of cabozantinib plus atezolizumab across clear cell RCC and non-clear cell RCC histologies, with a tolerable safety profile. Side effects were managed with dose modifications and supportive care measures.

Further evaluation of cabozantinib plus atezolizumab in RCC is ongoing in the phase III CONTACT-03 study, which is evaluating cabozantinib plus atezolizumab compared with cabozantinib alone in patients with clear cell RCC and non-clear cell RCC who received prior immune checkpoint inhibitor as a first- or second-line treatment.


Pal SK, McGregor B, Suárez, et al. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. JCO; Published online 7 September 2021. DOI:10.1200/JCO.21.00939


Προηγούμενο άρθροA celebration of peer review
Επόμενο άρθροPioneer in Autism Diagnosis And Treatment Dies At 97


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...